<DOC>
	<DOC>NCT01185691</DOC>
	<brief_summary>The primary objective of this study is to assess safety and feasibility of IMPELLA 2.5 in Acute Decompensated Heart Failure patients.</brief_summary>
	<brief_title>Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Major 1. Chronic heart failure patients, hospitalized due to decompensated heart failure (ADHF) with NYHA Class IIIIV symptoms (ADHF is defined by the presence of at least one of the following symptoms/signs: dyspnea w/orthopnea, jugular venous distension, peripheral edema +2, abdominal ascites, signs of CHF on chest XRay) 2. LVEF â‰¤ 40 % within the past 3 months Major 1. Acute Qwave myocardial infarction or Acute coronary syndrome within past 30 days 2. Cardiac surgery within the past 30 days 3. Implantation of cardiac resynchronization device within past 30 days or a possibility of implanting a biventricular pacer within 90 days of randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>